Choroideremia Stocks List
Symbol | Grade | Name | % Change | |
---|---|---|---|---|
FDMT | F | 4D Molecular Therapeutics, Inc. | -1.34 | |
NITE | C | Capitol Series Trust The Nightview Fund NITE | 0.00 |
Related Industries: Biotechnology
Symbol | Grade | Name | Weight | |
---|---|---|---|---|
HELX | D | Franklin Genomic Advancements ETF | 0.57 | |
IDNA | D | iShares Genomics Immunology and Healthcare ETF | 0.53 | |
SBIO | C | ALPS Medical Breakthroughs ETF | 0.38 | |
BBC | D | Virtus LifeSci Biotech Clinical Trials ETF | 0.37 | |
XBI | D | SPDR S&P Biotech ETF | 0.16 |
Compare ETFs
Date | Stock | Title |
---|---|---|
Sep 27 | NITE | Wynn Resorts' New York Casino Bid Could Act As A Positive Catalyst: Analyst |
- Choroideremia
Choroideremia (; CHM) is a rare, X-linked recessive form of hereditary retinal degeneration that affects roughly 1 in 50,000 males. The disease causes a gradual loss of vision, starting with childhood night blindness, followed by peripheral vision loss, and progressing to loss of central vision later in life. Progression continues throughout the individual's life, but both the rate of change and the degree of visual loss are variable among those affected, even within the same family.Choroideremia is caused by a loss-of-function mutation in the CHM gene which encodes Rab escort protein 1 (REP1), a protein involved in lipid modification of Rab proteins. While the complete mechanism of disease is not fully understood, the lack of a functional protein in the retina results in cell death and the gradual deterioration of the retinal pigment epithelium (RPE), photoreceptors, and the choroid.As of 2018, there is no treatment for choroideremia; however, retinal gene therapy clinical trials have demonstrated a possible treatment.
Popular Now
Recent Comments
- LillyMilly1 on LILM
- LillyMilly1 on LILM
- TraderMike on RYDE what a RIDE!!! Holy Crap!
- Crunching_The_Market on RYDE what a RIDE!!! Holy Crap!
- LillyMilly1 on LILM
From the Blog
Featured Articles